Successful products require substantial, consistent investment and a multifaceted approach to development and commercialization. Multiple strategies, real product-specific advantages that differentiate a product from key competitors, and the marketing muscle necessary to achieve share of voice are key to long-term success. Effective prelaunch planning and execution is required to shape and prepare the market and to ensure rapid adoption at launch. Companies are constantly faced with a series of choices. How those choices are made will ultimately determine the future success of the brand. There is substantial cost to developing and marketing potential blockbusters, and early commercial analysis and input is critical to the process. Prelaunch investments can be significant. Through a partnership involving research, clinical development, and commercial, we can hope to optimize the decision-making process, reduce the risk of investment, effectively shape products and their markets for launch success, and focus on areas of opportunity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
PhRMA Member Companies' R&D Expenditures for 2001 is estimated
U.S. Food and Drug Administration 2002. IDEC's Zeralin (Feb.), Gilead's Hepsera (Sep.), Seron's Rebif (Mar.), Amgen's Neulastaâ„¢ (Jan.), Pfizer's Vfend (May), Novartis' Zelnorm (July), Astrazerer's Faslodex (April) plus 4 others
Blauvelt B. Benchmarks for blockbuster launches. Pharmaceutical Executive, Vol. 23, pg. 53, Feb 2003
Daly, M. Lolassa; Pharmaceutical Executive Supplement, Vol. 24 March 2004
Fox, S. Market research 101. Pharmaceutical Executive. Vol. 21, May 2001
Gregson N, Sparrowhawk K, Muaskopf J, Paul J. Pricing medicines: Theory and practice, challenges and opportunities. Nature Drug Discovery 2005;4(2):121–130
Anonymous. Product Launches Report. Personal communication. 2001
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Lytle, T. (2007). Commercial Division. In: Evens, R.P. (eds) Drug and Biological Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69094-0_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-69094-0_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-32978-9
Online ISBN: 978-0-387-69094-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)